COMPASS Pathways
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Public
- Established
- 2016-06-13
- Employees
- 186
- Market Cap
- -
- Introduction
Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 102
- Registration Number
- NCT05733546
- Locations
- ๐บ๐ธ
Kadima Neuropsychiatry Institute, La Jolla, California, United States
๐บ๐ธClinical Neuroscience Solutions Inc, Jacksonville, Florida, United States
๐บ๐ธSunstone Therapies, Rockville, Maryland, United States
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 568
- Registration Number
- NCT05711940
- Locations
- ๐บ๐ธ
Clinical Innovations, Inc., Bellflower, California, United States
๐บ๐ธCatalina Research Institute, LLC, Montclair, California, United States
๐บ๐ธCITrials, Riverside, California, United States
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 255
- Registration Number
- NCT05624268
- Locations
- ๐บ๐ธ
University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States
๐บ๐ธProScience Research Group, Culver City, California, United States
๐บ๐ธCollaborative Neuroscience Network, LLC, Garden Grove, California, United States
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 32
- Registration Number
- NCT05481736
- Locations
- ๐บ๐ธ
Altman Clinical and Translational Research Institute, San Diego, California, United States
๐บ๐ธSheppard Pratt Health System, Baltimore, Maryland, United States
๐บ๐ธDell Medical School, Austin, Texas, United States
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 22
- Registration Number
- NCT05312151
- Locations
- ๐บ๐ธ
Sunstone Therapies, Rockville, Maryland, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
๐ฌ๐งKings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 19
- Registration Number
- NCT04739865
- Locations
- ๐บ๐ธ
Kadima Neuropsychiatry Institute, La Jolla, California, United States
๐ฎ๐ชSheaf House, Tallaght Hospital, Dublin, Ireland
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
- Conditions
- Treatment Resistant Depression
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 66
- Registration Number
- NCT04519957
- Locations
- ๐บ๐ธ
Kadima Neuropsychiatry Institute, La Jolla, California, United States
๐บ๐ธAltman Clinical and Translational Research Institute, University of California, San Diego, California, United States
๐บ๐ธMood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 233
- Registration Number
- NCT03775200
- Locations
- ๐บ๐ธ
Kadima Neuropsychiatry Institute, La Jolla, California, United States
๐บ๐ธAltman Clinical and Translational Research Institute, University of California, San Diego, California, United States
๐บ๐ธStanford Department of Psychiatry, Stanford, California, United States